Earnings season is in full swing, and Wall Avenue analysts named a slew of well-positioned shares heading into quarterly outcomes. These corporations are firing on all cylinders, and their shares have extra room to run. CNBC Professional combed via latest Wall Avenue analysis to search out shares with earnings upside. They embody Nvidia, Dover, Arista Networks , Xcel Vitality, Pfizer and Costco. Dover Shares of Dover, a maker of business merchandise, are down about 3.5% in October, however they’re too enticing to disregard, Oppenheimer stated. Analyst Bryan Blair wrote in a latest notice that buyers ought to benefit from the weak spot to build up shares. “We admire Dover’s important transformation through the years, shedding non-industrial belongings and establishing a extra streamlined multi-industry portfolio,” Blair stated. The agency stated it likes Dover’s big selection of companies, which incorporates local weather and sustainability applied sciences, in addition to clear power. The analyst additionally says Dover’s biopharma unit is underappreciated, with a gorgeous setup into subsequent yr. “Trying to 2024, the seemingly resurgence of biopharma, continued outgrowth of different secular progress markets and $40M-plus in carryover financial savings help continued earnings momentum,” Blair wrote. Dover just lately introduced it was buying FW Murphy Manufacturing Controls, a pure fuel compressor controls options firm that Blair says “levers momentum into 2024.” Dover is scheduled to report quarterly earnings subsequent week. Arista Networks It is shaping as much as be a giant quarter forward for the pc networking firm, in response to Evercore ISI. Analyst Amit Daryanani and his group added a tactical outperform to the inventory forward of earnings on Oct. 30. “Arista ought to proceed their monitor file of beating steering and it is doable we see yet another enhance to the total yr information,” he stated. The agency stated it expects no actual surprises from the corporate and that buyers ought to deal with upcoming 2024 occasions, comparable to the corporate’s analyst day. “We proceed to see a number of paths to double digit progress for Arista in 2024 and their analyst day ought to affirm this outlook,” Daryanani wrote. As well as, he stated buyers ought to look ahead to any commentary on how Arista is considering synthetic intelligence, as that is prone to be one other optimistic catalyst. In the meantime, shares are up 53% this yr. “Effectively Positioned for One other Beat and Increase,” Daryanani stated. Xcel Vitality Financial institution of America stated in a latest notice that the utility firm’s progress prospects are too enticing to disregard proper now. The agency upgraded the inventory to purchase from impartial forward of the corporate’s Oct. 27 earnings report. “In a sector with corporations largely taking part in protection given rate of interest and inflationary pressures, the XEL rising progress story comes throughout as all of the extra compelling,” analyst Julien Dumoulin-Smith stated. Xcel can be a key beneficiary of the Inflation Discount Act, in response to Dumoulin-Smith, who raised his worth goal on the inventory to $66 per share from $58. “Because the market has grown extra cautious across the utility outlook, we imagine XEL continues to ship strong earnings upside and a premium defensive core regulated story that buyers will proceed to gravitate to amid broader sector rotation,” he stated. Shares are down 17% this yr. Dover – Oppenheimer, outperform score “FW Murphy Deal Levers Momentum Into 2024. … Trying to 2024, seemingly resurgence of biopharma, continued outgrowth of different secular progress markets & $40M-plus in carryover financial savings help continued earnings momentum. … We admire DOV’s important transformation through the years, shedding non-industrial belongings & establishing a extra streamlined multi-industry portfolio. We imagine DOV is nicely positioned for sustainable core progress throughout platforms with EPS upside pushed by quantity leverage & steady working enhancements.” Xcel Vitality – Financial institution of America, purchase score “In a sector with corporations largely taking part in protection given rate of interest and inflationary pressures, the XEL rising progress story comes throughout as all of the extra compelling. … Because the market has grown extra cautious across the utility outlook, we imagine XEL continues to ship strong earnings upside and a premium defensive core regulated story that buyers will proceed to gravitate to amid broader sector rotation.” Costco – William Blair, outperform score “Whereas we see room for potential a number of enlargement in keeping with its latest common, we count on the inventory to primarily admire on sustainable earnings progress within the low-double-digit vary pushed by the rising attraction of its worth proposition, sturdy member engagement, warehouse enlargement efforts, and shareholder returns, with potential for extra earnings upside on a membership price enhance.” Pfizer – Cantor Fitzgerald, obese score “On Friday (10/13), PFE amended its US authorities Paxlovid provide settlement, lowered its full-year 2023 steering, & launched a price financial savings program. The latter two initiatives had been broadly anticipated & all three updates enhance earnings visibility into 2023+ which ought to take away an overhang on PFE’s inventory. … Put up the replace final Friday, we proceed to suppose it is a good time to take one other take a look at PFE’s inventory. Earnings expectations have been reset.” Arista Networks – Evercore ISI, outperform score “Effectively Positioned for One other Beat and Increase. Including to Tactical OP Record. … Arista ought to proceed their monitor file of beating steering and it is doable we see yet another enhance to the total yr information. … We proceed to see a number of paths to double digit progress for Arista in 2024 and their analyst day ought to affirm this outlook.” Nvidia – Jefferies, purchase score “AI and Automotive demand stays strong, whereas demand is weakening elsewhere, together with industrial purposes. … Semis Pricing is Steady, OCMs [original component manufacturers] Imagine the Put up-COVID Pricing Ranges are Right here to Keep Given Inflationary Surroundings. … Going into earnings season, we expect NVDA and AMAT have the very best likelihood to publish upside surprises.”
